Articles

Information integration

Genomenon and BC Platforms seek to combine their tech platforms to boost genomic research
Written byKelsey Kaustinen
| 3 min read

ZURICH, Switzerland & BOSTON—The first quarter of the year saw an announcement from BC Platforms and Genomenon of a collaboration aimed at rare diseases. Under this agreement, the companies will aim to integrate Genomenon’s Mastermind Genomic Search Engine with BC Platforms’ BC|GENOME, a genomic analysis and interpretation platform.

In addition, they will also integrate Mastermind with BC Platforms’ BC|INSIGHT to enable more complex genomic research via simplified genomic data annotations for artificial intelligence and/or machine learning efforts.

BC Platforms provides access to genomic/clinical data and samples from more than five million individuals, thanks to its network of partners, and has developed BCRQUEST.com, a Global Data Partner Network that makes genomic and clinical cohort data available for pharmaceutical and medical research and development.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 17 - Issue 5 | May 2021

May 2021

May 2021 issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue